Sign Out
Pregnancy: There are no studies in pregnant women. Women of reproductive potential should be advised to avoid becoming pregnant.
EGFR has been implicated in the control of pre-natal development. VECTIBIX has been shown to be an abortifacient in cynomolgus monkeys when administered during the period of organogenesis.
In women of childbearing potential, effective contraceptive measures must be used during treatment with VECTIBIX, and for 2 months following the last dose of VECTIBIX. If the patient becomes pregnant while receiving VECTIBIX, the patient should be apprised of the potential risk for loss of the pregnancy or potential hazard to the fetus (see PHARMACOLOGY: Toxicology: Preclinical safety data/Nonclinical toxicology under Actions).
Lactation: Because human IgG is secreted into human milk, VECTIBIX might also be secreted. The potential for absorption and harm to the infant after ingestion is unknown.
It is recommended that women discontinue nursing when during treatment with VECTIBIX and for 2 months after the last dose of VECTIBIX.
Fertility: No data are available on the effect of VECTIBIX on human fertility. See PHARMACOLOGY: Toxicology: Preclinical safety data/Nonclinical toxicology under Actions for the effects on fertility in nonclinical study in the monkey.
